Lundbeck
HLUN-B.CO
#2744
Rank
โ‚น613.66 B
Marketcap
โ‚น618.52
Share price
-0.80%
Change (1 day)
29.37%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Revenue for Lundbeck (HLUN-B.CO)

Revenue in 2026 (TTM): โ‚น358.48 Billion

According to Lundbeck's latest financial reports the company's current revenue (TTM ) is โ‚น386.32 Billion. In 2025 the company made a revenue of โ‚น341.25 Billion an increase over the revenue in the year 2024 that were of โ‚น272.64 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Lundbeck from 2009 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น358.48 B5.05%
2025 โ‚น341.25 B25.16%
2024 โ‚น272.64 B13.18%
2023 โ‚น240.89 B12.98%
2022 โ‚น213.21 B12.47%
2021 โ‚น189.57 B-5.45%
2020 โ‚น200.49 B8.23%
2019 โ‚น185.24 B-6.1%
2018 โ‚น197.28 B16.16%
2017 โ‚น169.84 B7.67%
2016 โ‚น157.73 B10.39%
2015 โ‚น142.89 B-4.71%
2014 โ‚น149.95 B-10.53%
2013 โ‚น167.59 B18.28%
2012 โ‚น141.69 B-9.42%
2011 โ‚น156.43 B32.92%
2010 โ‚น117.69 B-2.35%
2009 โ‚น120.53 B